453 related articles for article (PubMed ID: 24245762)
1. QSAR based design of new antitubercular compounds: improved isoniazid derivatives against multidrug-resistant TB.
Martins F; Ventura C; Santos S; Viveiros M
Curr Pharm Des; 2014; 20(27):4427-54. PubMed ID: 24245762
[TBL] [Abstract][Full Text] [Related]
2. Isoniazid derivatives and their anti-tubercular activity.
Hu YQ; Zhang S; Zhao F; Gao C; Feng LS; Lv ZS; Xu Z; Wu X
Eur J Med Chem; 2017 Jun; 133():255-267. PubMed ID: 28390957
[TBL] [Abstract][Full Text] [Related]
3.
Jagadeb M; Rath SN; Sonawane A
J Biomol Struct Dyn; 2019 Aug; 37(13):3388-3398. PubMed ID: 30132739
[TBL] [Abstract][Full Text] [Related]
4. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity.
Martins F; Santos S; Ventura C; Elvas-Leitão R; Santos L; Vitorino S; Reis M; Miranda V; Correia HF; Aires-de-Sousa J; Kovalishyn V; Latino DA; Ramos J; Viveiros M
Eur J Med Chem; 2014 Jun; 81():119-38. PubMed ID: 24836065
[TBL] [Abstract][Full Text] [Related]
6. Genotypic Analysis of Genes Associated with Independent Resistance and Cross-Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis Clinical Isolates.
Rueda J; Realpe T; Mejia GI; Zapata E; Rozo JC; Ferro BE; Robledo J
Antimicrob Agents Chemother; 2015 Dec; 59(12):7805-10. PubMed ID: 26369965
[TBL] [Abstract][Full Text] [Related]
7. Mutations of rpoB, katG, inhA and ahp genes in rifampicin and isoniazid-resistant Mycobacterium tuberculosis in Kyrgyz Republic.
Isakova J; Sovkhozova N; Vinnikov D; Goncharova Z; Talaibekova E; Aldasheva N; Aldashev A
BMC Microbiol; 2018 Mar; 18(1):22. PubMed ID: 29566660
[TBL] [Abstract][Full Text] [Related]
8. DFT based QSAR/QSPR models in the development of novel anti-tuberculosis drugs targeting Mycobacterium tuberculosis.
Rajkhowa S; Deka RC
Curr Pharm Des; 2014; 20(27):4455-73. PubMed ID: 24245759
[TBL] [Abstract][Full Text] [Related]
9. QSAR-driven design, synthesis and discovery of potent chalcone derivatives with antitubercular activity.
Gomes MN; Braga RC; Grzelak EM; Neves BJ; Muratov E; Ma R; Klein LL; Cho S; Oliveira GR; Franzblau SG; Andrade CH
Eur J Med Chem; 2017 Sep; 137():126-138. PubMed ID: 28582669
[TBL] [Abstract][Full Text] [Related]
10. Early detection of multidrug- and pre-extensively drug-resistant tuberculosis from smear-positive sputum by direct sequencing.
Chen J; Peng P; Du Y; Ren Y; Chen L; Rao Y; Wang W
BMC Infect Dis; 2017 Apr; 17(1):300. PubMed ID: 28438132
[TBL] [Abstract][Full Text] [Related]
11. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
12. Molecular analysis of isoniazid-resistant Mycobacterium tuberculosis isolates in Uruguay.
Greif G; Coitinho C; Rivas C; van Ingen J; Robello C
Int J Tuberc Lung Dis; 2012 Jul; 16(7):947-9. PubMed ID: 22507192
[TBL] [Abstract][Full Text] [Related]
13. The impact of combined gene mutations in inhA and ahpC genes on high levels of isoniazid resistance amongst katG non-315 in multidrug-resistant tuberculosis isolates from China.
Liu L; Jiang F; Chen L; Zhao B; Dong J; Sun L; Zhu Y; Liu B; Zhou Y; Yang J; Zhao Y; Jin Q; Zhang X
Emerg Microbes Infect; 2018 Nov; 7(1):183. PubMed ID: 30446638
[TBL] [Abstract][Full Text] [Related]
14. Genetic diversity of Mycobacterium tuberculosis isoniazid monoresistant and multidrug-resistant in Rio Grande do Sul, a tuberculosis high-burden state in Brazil.
Esteves LS; Dalla Costa ER; Vasconcellos SEG; Vargas A; Ferreira Junior SLM; Halon ML; Ribeiro MO; Rodenbusch R; Gomes HM; Suffys PN; Rossetti MLR
Tuberculosis (Edinb); 2018 May; 110():36-43. PubMed ID: 29779771
[TBL] [Abstract][Full Text] [Related]
15. Molecular investigation of active binding site of isoniazid (INH) and insight into resistance mechanism of S315T-MtKatG in Mycobacterium tuberculosis.
Srivastava G; Tripathi S; Kumar A; Sharma A
Tuberculosis (Edinb); 2017 Jul; 105():18-27. PubMed ID: 28610784
[TBL] [Abstract][Full Text] [Related]
16. Current status of multidrug resistant tuberculosis in a tertiary care hospital of East Delhi.
Sagar T; Singh NP; Kashyap B; Kaur IR
J Postgrad Med; 2013; 59(3):173-6. PubMed ID: 24029192
[TBL] [Abstract][Full Text] [Related]
17. Molecular and phenotypic characterisation of Mycobacterium tuberculosis resistant to anti-tuberculosis drugs.
Imperiale BR; Zumárraga MJ; Di Giulio AB; Cataldi AA; Morcillo NS
Int J Tuberc Lung Dis; 2013 Aug; 17(8):1088-93. PubMed ID: 23827034
[TBL] [Abstract][Full Text] [Related]
18. Emergence and selection of isoniazid and rifampin resistance in tuberculosis granulomas.
Pienaar E; Linderman JJ; Kirschner DE
PLoS One; 2018; 13(5):e0196322. PubMed ID: 29746491
[TBL] [Abstract][Full Text] [Related]
19. QSAR Studies, Synthesis and Antibacterial Assessment of New Inhibitors Against Multidrug-Resistant Mycobacterium tuberculosis.
Kovalishyn V; Brovarets V; Blagodatnyi V; Kopernyk I; Hodyna D; Chumachenko S; Shablykin O; Kozachenko O; Vovk M; Barus M; Bratenko M; Metelytsia L
Curr Drug Discov Technol; 2017; 14(1):25-38. PubMed ID: 27829331
[TBL] [Abstract][Full Text] [Related]
20. Profile of drug-resistant-conferring mutations among new and previously treated pulmonary tuberculosis cases from Aligarh region of Northern India.
Ahmed S; Shukla I; Fatima N; Varshney SK; Shameem M; Tayyaba U
Int J Mycobacteriol; 2018; 7(4):315-327. PubMed ID: 30531028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
